Inotiv Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Inotiv Inc's ROI in the second quarter of 2026?
Inotiv Inc recorded a cumulative net loss of $-87 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -27.95%.

Within the Healthcare sector 354 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2591 to 3061.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Mar 31 2026) II. Quarter	(Dec 31 2025) I. Quarter	(Sep 30 2025) IV. Quarter	(Jun 30 2025) III. Quarter	(Mar 31 2025) II. Quarter
Y / Y Investment Change TTM	-46.26 %	-8.03 %	12.5 %	30.38 %	-7.85 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	162	196	214	672	700
Return On Investment (TTM)	-27.95 %	-15.57 %	-12.2 %	-11.84 %	-15.26 %
NOTV's Overall Ranking	# 3061	# 2591	# 2906	# 2093	# 2961
Seq. Investment Change TTM	-30.18 %	-20.8 %	-16.6 %	16.53 %	19.48 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-87	-69	-69	-80	-88

NOTV Company Profile >> Back to NOTV Roi Comparisons >> See Annual NOTV Return On Investment

Return On Investment NOTV's Ranking
Within:	No.
Industry	# 19
Sector	# 355
Overall	# 3061

Return On Investment Statistics
High	Average	Low
9.65 %	-10.66 %	-45.1 %
(Jun 30 2015)		(Jun 30 2023)

News about Inotiv Inc Return on Investment ROI

Inotiv, Inc. Faces Setbacks as Shares Plummet and Net Losses Mount

June 10, 2024

Inotiv, Inc. (Nasdaq: NOTV), a renowned contract research organization focused on nonclinical and analytical drug discovery and development services, has recently experienced a series of challenges. The company s shares have plummeted by a staggering 64% over the past month, reflecting investor concerns. Furthermore, Inotiv s financial reports indicate a cumulative net loss of $71 million during the 12 months ending in the second quarter of 2024, resulting in a worrying negative return on investment (ROI) of -11.4%.
These developments highlight the difficulties that Inotiv currently faces in the highly competitive healthcare sector. As the company struggles to turn a profit, 179 other companies within the sector have managed to achieve higher returns on investment. Inotiv s rivals appear to be outpacing the organization, leaving investors wary of its future prospects.

Inotiv, Inc. Partners with Vanguard to Insourcing Transportation Operations Amidst Cumulative Net Losses: Assessing Strategies for Growth

December 6, 2023

Inotiv, Inc. Announces Plan to Insourcing North American Transportation Operations Despite Cumulative Net Losses
Inotiv, Inc., a prominent contract research organization specializing in nonclinical and analytical drug discovery and development services, as well as research models and related products and services, has recently revealed its intention to partner with Vanguard Supply Chain Solutions LLC to bring its North American transportation operations in-house. This decision comes in light of the company s recorded cumulative net loss of $-338 million during the 12-month period ending in the third quarter of 2023, resulting in a negative return on investment (ROI) of -45.1%.
The partnership with Vanguard Supply Chain Solutions LLC will allow Inotiv to integrate its transportation operations internally, aiming for greater control and potentially cost savings. By insourcing these operations, the Company expects to streamline its logistics processes and improve efficiency, ensuring smoother transportation of vital research materials, samples, and products throughout North America.

Financial Statements
Inotiv Inc's II. Quarter Investments	$ 162 Millions	NOTV's Balance sheet
Inotiv Inc's II. Quarter Income	$ -32 Millions	Quarterly NOTV's Income Statement
NOTV's Income by Division		See NOTV's Income by Division

NOTV Annual Return On Investment	(Sep 30 2025) 2025	(Sep 30 2024) 2024	(Sep 30 2023) 2023	(Sep 30 2022) 2022	(Sep 30 2021) 2021
Total Investments in Millions	214	662	724	798	267
Y / Y Investment Growth	-67.64 %	-8.48 %	-9.34 %	199.23 %	790.61 %
Net Income in Millions	-69	-109	-105	-337	11
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-32.02 %	-16.44 %	-14.5 %	-42.19 %	4.08 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Laboratories Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
NOTV's Roi Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for NOTV's Competitors
Subscribers only: Roi for Inotiv Inc's Suppliers
Subscribers only: Return On Investment for NOTV's Customers

Other Ratios
NOTV's Roa	NOTV's Inventory Turnover Ratio	NOTV's Growth Rates	NOTV's Dividend Statistics
	NOTV's Profitability Ratios	NOTV's Asset Turnover Ratio	NOTV's Dividend Growth
NOTV's Roe	NOTV's Valuation Ratios	NOTV's Financial Strength Ratios	NOTV's Dividend Payout Ratio

Companies with similar Return On Investment at Mar 31 2026, within Healthcare Sector

ROI

Date modified: 2026-09-26T06:55:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.